drugset / Trial / NCT00223951

Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers

NCT00223951

Phase 3 Completed 900 enrolled Vistakon Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety of R89674 0.25% ophthalmic solution in healthy normal volunteers

Timeline

Start
2005-09
Primary completion
2005-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Alcaftadine Small molecule 0.25 % Other

Indications

No indication recorded.